Display options
Cite
Turesson I, Bjorkholm M, Blimark CH, et al. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol. 2018;doi: 10.1111/ejh.13083.
Turesson, I., Bjorkholm, M., Blimark, C. H., Kristinsson, S., Velez, R., & Landgren, O. (2018). Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. European journal of haematology, . https://doi.org/10.1111/ejh.13083
Turesson, Ingemar, et al. "Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival." European journal of haematology vol. (2018). doi: https://doi.org/10.1111/ejh.13083
Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol. 2018 Apr 20; doi: 10.1111/ejh.13083. Epub 2018 Apr 20. PMID: 29676004; PMCID: PMC6195866.
Copy Download .nbib Format: NLM
Share it on

Eur J Haematol. 2018 Apr 20; doi: 10.1111/ejh.13083. Epub 2018 Apr 20.

Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival.

European journal of haematology

Ingemar Turesson, Magnus Bjorkholm, Cecilie Hveding Blimark, Sigurdur Kristinsson, Ramon Velez, Ola Landgren

Affiliations

  1. Department of Haematology, Skane University Hospital, Malmo, Sweden.
  2. Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
  3. Department of Hematology, Sahlgrenska University Hospital and Institution of Internal Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
  4. Department of Medicine, University of Iceland, Reykjavik, Iceland.
  5. Department of Medicine, Section on General Internal Medicine, Wake Forest School of Medicine, Winston Salem, NC, USA.
  6. Myeloma Service, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

PMID: 29676004 PMCID: PMC6195866 DOI: 10.1111/ejh.13083

Abstract

The incidence of multiple myeloma is characterized by a steep increase with advancing age. Dramatic improvements in survival have been reported in clinical trials; however, elderly patients are generally underrepresented in these. The aims of this study are to review patterns of incidence and survival in multiple myeloma in the general population. We searched PubMed for population-based studies on trends in incidence and survival published between January 1, 2000 and June 30, 2017 and based on regional or national cancer registries and report the following results of the review. The age-adjusted incidence of multiple myeloma has increased during the second half of the twentieth century in some countries but remained stable in areas with high case ascertainment and access to universal medical care. The crude incidence is increasing globally due to an aging population. Survival rates have improved, and 5-year relative survival rates are now around 50% and over 60% in patients 65-70 years or younger. Preliminary data suggest a 3-fold increase in the prevalence of multiple myeloma. We conclude that the number of multiple myeloma patients is increasing in the general population due to (i) aging populations and (ii) more patients living longer due to modern drugs.

© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Keywords: incidence; multiple myeloma; overall survival; prevalence; trends

References

  1. Cancer Epidemiol. 2015 Oct;39(5):693-9 - PubMed
  2. N Engl J Med. 1996 Jul 11;335(2):91-7 - PubMed
  3. Eur J Cancer. 2006 Jul;42(11):1661-70 - PubMed
  4. N Engl J Med. 2016 Apr 28;374(17):1621-34 - PubMed
  5. Blood. 2011 Aug 4;118(5):1239-47 - PubMed
  6. CA Cancer J Clin. 2016 Nov 12;66(6):443-459 - PubMed
  7. Blood. 2018 Jan 18;131(3):301-310 - PubMed
  8. J Natl Cancer Inst. 1982 Aug;69(2):387-92 - PubMed
  9. Leukemia. 2009 Jun;23(6):1152-7 - PubMed
  10. Blood Adv. 2017 Jan 4;1(4):282-287 - PubMed
  11. Blood. 2008 Mar 1;111(5):2516-20 - PubMed
  12. Cancer. 2004 Dec 1;101(11):2667-74 - PubMed
  13. BMC Cancer. 2010 Mar 01;10:74 - PubMed
  14. Blood Cancer J. 2015 Sep 18;5:e349 - PubMed
  15. J Intern Med. 2017 Apr;281(4):365-382 - PubMed
  16. Blood. 2015 Jan 8;125(2):410-2 - PubMed
  17. Cancer. 1981 Dec 1;48(11):2547-54 - PubMed
  18. Cancer. 2007 Aug 15;110(4):896-905 - PubMed
  19. Blood. 2008 Mar 1;111(5):2521-6 - PubMed
  20. N Engl J Med. 2016 Aug 25;375(8):754-66 - PubMed
  21. Oncologist. 2011;16(11):1600-3 - PubMed
  22. Int J Cancer. 2007;120 Suppl 12:40-61 - PubMed
  23. Int J Cancer. 2015 Jun 1;136(11):2649-58 - PubMed
  24. Lancet Oncol. 2014 Aug;15(9):931-42 - PubMed
  25. Haematologica. 2018 Mar;103(3):506-513 - PubMed
  26. Int J Cancer. 2015 Sep 1;137(5):1217-23 - PubMed
  27. Br J Haematol. 2014 Mar;164(5):684-93 - PubMed
  28. Acta Oncol. 2016;55 Suppl 1:98-107 - PubMed
  29. Blood. 2010 Dec 16;116(25):5501-6 - PubMed
  30. Leuk Lymphoma. 2016;57(3):585-9 - PubMed
  31. J Clin Oncol. 2007 May 20;25(15):1993-9 - PubMed
  32. Br J Haematol. 2015 Oct;171(2):189-196 - PubMed
  33. Leukemia. 2014 May;28(5):1122-8 - PubMed
  34. Leukemia. 2009 Oct;23(10):1691-7 - PubMed
  35. Eur J Cancer. 2010 Jan;46(1):160-9 - PubMed
  36. Br J Haematol. 2013 Oct;163(1):40-6 - PubMed
  37. Haematologica. 2018 Sep;103(9):e412-e415 - PubMed
  38. Leukemia. 2013 Jan;27(1):226-32 - PubMed
  39. Int J Cancer. 2007 Nov 15;121(10):2260-6 - PubMed
  40. Lancet. 2017 Feb 4;389(10068):519-527 - PubMed
  41. Mayo Clin Proc. 2010 Mar;85(3):225-30 - PubMed
  42. J Clin Oncol. 2010 Feb 10;28(5):830-4 - PubMed
  43. N Engl J Med. 2015 Jan 8;372(2):142-52 - PubMed
  44. J Clin Oncol. 2013 Feb 1;31(4):448-55 - PubMed
  45. BMJ Open. 2016 Jan 21;6(1):e009584 - PubMed
  46. N Engl J Med. 2016 Oct 6;375(14):1319-1331 - PubMed
  47. Leukemia. 2014 Jun;28(6):1346-8 - PubMed
  48. N Engl J Med. 2003 May 8;348(19):1875-83 - PubMed

Publication Types

Grant support